TP53 and head and neck squamous cell carcinoma: This may be explained by the presence of an intact (non-mutated) P53 gene in HPV+ SCCHN, rendering them more vulnerable to therapies than HPV− SCCHN, which are known for their higher mutational burden [55,56,57].